Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 3
1983 1
1985 3
1986 7
1987 17
1988 14
1989 8
1990 14
1991 29
1992 5
1993 14
1994 18
1995 19
1996 26
1997 15
1998 19
1999 15
2000 18
2001 16
2002 21
2003 20
2004 15
2005 19
2006 24
2007 19
2008 20
2009 9
2010 11
2011 13
2012 8
2013 13
2014 9
2015 9
2016 12
2017 7
2018 8
2019 5
2020 2
2021 3
Text availability
Article attribute
Article type
Publication date

Search Results

486 results
Results by year
Filters applied: . Clear all
Page 1
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.
Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, Ford I, Cruickshank JK, Caulfield MJ, Salsbury J, Mackenzie I, Padmanabhan S, Brown MJ; British Hypertension Society's PATHWAY Studies Group. Williams B, et al. Lancet. 2015 Nov 21;386(10008):2059-2068. doi: 10.1016/S0140-6736(15)00257-3. Epub 2015 Sep 20. Lancet. 2015. PMID: 26414968 Free PMC article. Clinical Trial.
After 21 were excluded, 285 patients received spironolactone, 282 doxazosin, 285 bisoprolol, and 274 placebo; 230 patients completed all treatment cycles. The average reduction in home systolic blood pressure by spironolactone was superior to placebo (-870 mm Hg [95% CI -9 …
After 21 were excluded, 285 patients received spironolactone, 282 doxazosin, 285 bisoprolol, and 274 placebo; 230 patients completed …
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM Jr, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA; Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. McConnell JD, et al. N Engl J Med. 2003 Dec 18;349(25):2387-98. doi: 10.1056/NEJMoa030656. N Engl J Med. 2003. PMID: 14681504 Free article. Clinical Trial.
The reduction in risk associated with combination therapy (66 percent for the comparison with placebo, P<0.001) was significantly greater than that associated with doxazosin (P<0.001) or finasteride (P<0.001) alone. The risks of acute urinary retention and the nee …
The reduction in risk associated with combination therapy (66 percent for the comparison with placebo, P<0.001) was significantly greater …
Efficacy of α-Blockers on Hemodynamic Control during Pheochromocytoma Resection: A Randomized Controlled Trial.
Buitenwerf E, Osinga TE, Timmers HJLM, Lenders JWM, Feelders RA, Eekhoff EMW, Haak HR, Corssmit EPM, Bisschop PHLT, Valk GD, Veldman RG, Dullaart RPF, Links TP, Voogd MF, Wietasch GJKG, Kerstens MN. Buitenwerf E, et al. J Clin Endocrinol Metab. 2020 Jul 1;105(7):2381-91. doi: 10.1210/clinem/dgz188. J Clin Endocrinol Metab. 2020. PMID: 31714582 Free PMC article. Clinical Trial.
RESULTS: Median cumulative time outside blood pressure targets was 11.1% (interquartile range [IQR]: 4.3-20.6] in the phenoxybenzamine group compared to 12.2% (5.3-20.2)] in the doxazosin group (P = .75, r = 0.03). The hemodynamic instability score was 38.0 (28.8-58.0) and …
RESULTS: Median cumulative time outside blood pressure targets was 11.1% (interquartile range [IQR]: 4.3-20.6] in the phenoxybenzamine group …
Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study.
Johnson K, Oparil S, Davis BR, Tereshchenko LG. Johnson K, et al. J Am Heart Assoc. 2019 Apr 16;8(8):e011961. doi: 10.1161/JAHA.119.011961. J Am Heart Assoc. 2019. PMID: 30943832 Free PMC article. Clinical Trial.
We studied the extent to which blood pressure ( BP ) change and evolving LVH contribute to the effect that lisinopril, doxazosin, and amlodipine have on HF compared with chlorthalidone. ...After full adjustment, evolving ECG LVH mediated 4% of the effect of doxazosin
We studied the extent to which blood pressure ( BP ) change and evolving LVH contribute to the effect that lisinopril, doxazosin, and …
Combination Therapy Is Superior to Sequential Monotherapy for the Initial Treatment of Hypertension: A Double-Blind Randomized Controlled Trial.
MacDonald TM, Williams B, Webb DJ, Morant S, Caulfield M, Cruickshank JK, Ford I, Sever P, Mackenzie IS, Padmanabhan S, McCann GP, Salsbury J, McInnes G, Brown MJ; British Hypertension Society Programme of Prevention And Treatment of Hypertension With Algorithm‐based Therapy (PATHWAY). MacDonald TM, et al. J Am Heart Assoc. 2017 Nov 18;6(11):e006986. doi: 10.1161/JAHA.117.006986. J Am Heart Assoc. 2017. PMID: 29151036 Free PMC article. Clinical Trial.
In phase 2 (weeks 17-32), all patients received losartan 100 mg and hydrochlorothiazide 12.5 to 25 mg. In phase 3 (weeks 33-52), amlodipine with or without doxazosin could be added to achieve target BP. Hierarchical primary outcomes were the difference from baseline in hom …
In phase 2 (weeks 17-32), all patients received losartan 100 mg and hydrochlorothiazide 12.5 to 25 mg. In phase 3 (weeks 33-52), amlodipine …
A comparison of efficacy of doxazosin 4 and 8 mg in medical expulsive therapy of distal ureteral stones: a prospective randomized clinical trial.
Sen H, Erturhan S, Sadioglu E, Bayrak O, Seckiner İ. Sen H, et al. Urolithiasis. 2017 Oct;45(5):461-464. doi: 10.1007/s00240-016-0927-0. Epub 2016 Oct 7. Urolithiasis. 2017. PMID: 27717996 Clinical Trial.
All patients were randomly divided into three groups: Group 1 included 25 patients receiving 4 mg doxazosin. Group 2 included 22 patients receiving 8 mg doxazosin. Diclofenac 100 mg p.o. and daily 1500-2000 cc hydration were advised to the patients in Groups 1 and 2 …
All patients were randomly divided into three groups: Group 1 included 25 patients receiving 4 mg doxazosin. Group 2 included 22 pati …
Comparing the effectiveness of intranasal desmopressin and doxazosin in men with nocturia: a pilot randomized clinical trial.
Ceylan C, Ceylan T, Doluoglu OG, Yuksel S, Agras K. Ceylan C, et al. Urol J. 2013 Sep 26;10(3):993-8. Urol J. 2013. PMID: 24078508 Clinical Trial.
PURPOSE: We aimed to compare the effectiveness of intranasal desmopressin and doxazosin treatments in patients with nocturia and benign prostatic hyperplasia (BPH). ...Improvements in number of nocturia, residual urine volume, quality of life scores and peak urinary flow r …
PURPOSE: We aimed to compare the effectiveness of intranasal desmopressin and doxazosin treatments in patients with nocturia and beni …
Comparison of the efficacy of isosorbide mononitrate and doxazosin in the treatment of lower urinary tract symptoms and benign prostatic hyperplasia: a randomized clinical trial.
Tarhan F, Çelik O, Tosun Ç, Faydacı G, Eryıldırım B. Tarhan F, et al. Urol Int. 2014;93(1):17-21. doi: 10.1159/000357034. Epub 2014 Mar 13. Urol Int. 2014. PMID: 24643055 Clinical Trial.
OBJECTIVE: We aimed to compare the efficacy of isosorbide mononitrate and doxazosin in the treatment of lower urinary tract symptoms (LUTS). ...All patients were evaluated with uroflowmetry, post-void residual (PVR) urine, prostate volume, International Prostate Symptom Sc …
OBJECTIVE: We aimed to compare the efficacy of isosorbide mononitrate and doxazosin in the treatment of lower urinary tract symptoms …
The effect of doxazosin, finasteride and combination therapy on nocturia in men with benign prostatic hyperplasia.
Johnson TM 2nd, Burrows PK, Kusek JW, Nyberg LM, Tenover JL, Lepor H, Roehrborn CG; Medical Therapy of Prostatic Symptoms Research Group. Johnson TM 2nd, et al. J Urol. 2007 Nov;178(5):2045-50; discussion 2050-1. doi: 10.1016/j.juro.2007.07.013. Epub 2007 Sep 17. J Urol. 2007. PMID: 17869295 Clinical Trial.
Mean nocturia was reduced at 1 year by 0.35, 0.40, 0.54 and 0.58 in the placebo, finasteride, doxazosin and combination groups, respectively. Reductions with doxazosin and combination therapy were statistically greater than with placebo (p <0.05). At 4 years noct …
Mean nocturia was reduced at 1 year by 0.35, 0.40, 0.54 and 0.58 in the placebo, finasteride, doxazosin and combination groups, respe …
Guidelines for antihypertensive treatment: an update after the ALLHAT study.
Salvetti A, Ghiadoni L. Salvetti A, et al. J Am Soc Nephrol. 2004 Jan;15 Suppl 1:S51-4. doi: 10.1097/01.asn.0000093242.48333.3b. J Am Soc Nephrol. 2004. PMID: 14684673 Free article. Review.
Its claim of the superiority of chlorthalidone was based on some secondary outcomes, principally represented by (1) an increased incidence of stroke in the doxazosin and lisinopril arms, an effect that might be explained by differences in systolic BP; (2) greater morbidity …
Its claim of the superiority of chlorthalidone was based on some secondary outcomes, principally represented by (1) an increased incidence o …
486 results